215 related articles for article (PubMed ID: 28373289)
1. miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.
Mody HR; Hung SW; Pathak RK; Griffin J; Cruz-Monserrate Z; Govindarajan R
Mol Cancer Res; 2017 Aug; 15(8):1029-1039. PubMed ID: 28373289
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.
Mody HR; Hung SW; AlSaggar M; Griffin J; Govindarajan R
Mol Cancer Res; 2016 Nov; 14(11):1124-1135. PubMed ID: 27624777
[TBL] [Abstract][Full Text] [Related]
3. miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting
van Kampen JGM; van Hooij O; Jansen CF; Smit FP; van Noort PI; Schultz I; Schaapveld RQJ; Schalken JA; Verhaegh GW
Cancer Res; 2017 Apr; 77(8):2008-2017. PubMed ID: 28209612
[TBL] [Abstract][Full Text] [Related]
4. Epigenetically-Regulated MicroRNA-9-5p Suppresses the Activation of Hepatic Stellate Cells via TGFBR1 and TGFBR2.
Yu F; Chen B; Fan X; Li G; Dong P; Zheng J
Cell Physiol Biochem; 2017; 43(6):2242-2252. PubMed ID: 29073595
[TBL] [Abstract][Full Text] [Related]
5. miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer.
Hiramoto H; Muramatsu T; Ichikawa D; Tanimoto K; Yasukawa S; Otsuji E; Inazawa J
Sci Rep; 2017 Jun; 7(1):4002. PubMed ID: 28638102
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
7. MALAT1 Modulates TGF-β1-Induced Endothelial-to-Mesenchymal Transition through Downregulation of miR-145.
Xiang Y; Zhang Y; Tang Y; Li Q
Cell Physiol Biochem; 2017; 42(1):357-372. PubMed ID: 28535533
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition.
Li LQ; Pan D; Chen Q; Zhang SW; Xie DY; Zheng XL; Chen H
Cell Physiol Biochem; 2018; 47(4):1533-1545. PubMed ID: 29940566
[TBL] [Abstract][Full Text] [Related]
9. Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-β/drosophila mothers against decapentaplegic pathway and angiogenesis-associated microRNAs.
Lin SZ; Xu JB; Ji X; Chen H; Xu HT; Hu P; Chen L; Guo JQ; Chen MY; Lu D; Wang ZH; Tong HF
Mol Med Rep; 2015 Oct; 12(4):5865-71. PubMed ID: 26238071
[TBL] [Abstract][Full Text] [Related]
10. SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.
Hong S; Noh H; Teng Y; Shao J; Rehmani H; Ding HF; Dong Z; Su SB; Shi H; Kim J; Huang S
Neoplasia; 2014 Apr; 16(4):279-90.e1-5. PubMed ID: 24746361
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer.
Mishra S; Deng JJ; Gowda PS; Rao MK; Lin CL; Chen CL; Huang T; Sun LZ
Oncogene; 2014 Jul; 33(31):4097-106. PubMed ID: 24037531
[TBL] [Abstract][Full Text] [Related]
12. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846.
Sugano T; Masuda M; Takeshita F; Motoi N; Hirozane T; Goto N; Kashimoto S; Uno Y; Moriyama H; Sawa M; Nagakawa Y; Tsuchida A; Seike M; Gemma A; Yamada T
Br J Cancer; 2021 Jan; 124(1):228-236. PubMed ID: 33244122
[TBL] [Abstract][Full Text] [Related]
14. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
[TBL] [Abstract][Full Text] [Related]
16. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
Yu S; Wang M; Zhang H; Guo X; Qin R
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
[TBL] [Abstract][Full Text] [Related]
17. Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model.
Boreddy SR; Srivastava SK
Oncogene; 2013 Aug; 32(34):3980-91. PubMed ID: 22986522
[TBL] [Abstract][Full Text] [Related]
18. miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2.
Harazono Y; Muramatsu T; Endo H; Uzawa N; Kawano T; Harada K; Inazawa J; Kozaki K
PLoS One; 2013; 8(5):e62757. PubMed ID: 23690952
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway.
Tu X; Zhang H; Zhang J; Zhao S; Zheng X; Zhang Z; Zhu J; Chen J; Dong L; Zang Y; Zhang J
J Pathol; 2014 Sep; 234(1):46-59. PubMed ID: 24817606
[TBL] [Abstract][Full Text] [Related]
20. MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer.
Qu Y; Zhang H; Duan J; Liu R; Deng T; Bai M; Huang D; Li H; Ning T; Zhang L; Wang X; Ge S; Zhou L; Zhong B; Ying G; Ba Y
Oncotarget; 2016 May; 7(22):33286-96. PubMed ID: 27120811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
